Search research articles
Contact Us
Filters
Showing results (1-10 of 52) with videos related to
Page
of 6
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis
Youwen Zhu, Kun Liu, Hong Zhu
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 20, 2024
Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis
Youwen Zhu, Kun Liu, Hong Zhu
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 18, 2023
Immune checkpoint inhibitor for patients with advanced biliary tract cancer: A cost-effectiveness analysis
Youwen Zhu, Kun Liu, Hong Zhu
Therapeutic Advances in Gastroenterology
|
October 7, 2024
TAS-102 with or without bevacizumab treatment for patients with metastatic colorectal cancer: a multi-country cost-effectiveness analysis
Youwen Zhu, Kun Liu, Hong Zhu
Journal of Gynecologic Oncology
|
June 10, 2024
Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis
Youwen Zhu, Kun Liu, Hong Zhu
Journal of Gynecologic Oncology
|
July 7, 2025
International cost-effectiveness analysis of chemoradiotherapy plus pembrolizumab for locally advanced cervical cancer
Kun Liu, Youwen Zhu, Hong Zhu
Frontiers in Immunology
|
January 30, 2023
Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis
Kun Liu, Youwen Zhu, Hong Zhu
Experimental Hematology & Oncology
|
February 12, 2026
Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer
Youwen Zhu, Kun Liu, Hong Zhu
Translational Lung Cancer Research
|
September 15, 2025
International cost-effectiveness analysis of durvalumab consolidation treatment after chemoradiotherapy for patients with limited-stage small-cell lung cancer
Kun Liu, Youwen Zhu, Hong Zhu
Advances in Therapy
|
March 4, 2023
Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis
Kun Liu, Youwen Zhu, Yangying Zhou, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 52) with videos related to
Sort By:
Page
of 6
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis
Youwen Zhu, Kun Liu, Hong Zhu
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 20, 2024
Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis
Youwen Zhu, Kun Liu, Hong Zhu
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 18, 2023
Immune checkpoint inhibitor for patients with advanced biliary tract cancer: A cost-effectiveness analysis
Youwen Zhu, Kun Liu, Hong Zhu
Therapeutic Advances in Gastroenterology
|
October 7, 2024
TAS-102 with or without bevacizumab treatment for patients with metastatic colorectal cancer: a multi-country cost-effectiveness analysis
Youwen Zhu, Kun Liu, Hong Zhu
Journal of Gynecologic Oncology
|
June 10, 2024
Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis
Youwen Zhu, Kun Liu, Hong Zhu
Journal of Gynecologic Oncology
|
July 7, 2025
International cost-effectiveness analysis of chemoradiotherapy plus pembrolizumab for locally advanced cervical cancer
Kun Liu, Youwen Zhu, Hong Zhu
Frontiers in Immunology
|
January 30, 2023
Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis
Kun Liu, Youwen Zhu, Hong Zhu
Experimental Hematology & Oncology
|
February 12, 2026
Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer
Youwen Zhu, Kun Liu, Hong Zhu
Translational Lung Cancer Research
|
September 15, 2025
International cost-effectiveness analysis of durvalumab consolidation treatment after chemoradiotherapy for patients with limited-stage small-cell lung cancer
Kun Liu, Youwen Zhu, Hong Zhu
Advances in Therapy
|
March 4, 2023
Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis
Kun Liu, Youwen Zhu, Yangying Zhou, et al.
Page
of 6